Tumor Marker Tests Explained- CA-125, PSA, and CEA

Home / Blog / Tumor Marker Tests Explained: CA-125, PSA, and CEA

Tumor Marker Tests Explained: CA-125, PSA, and CEA

Tumor marker tests are blood tests that measure substances produced by cancer cells or by the body in response to cancer. While they are rarely used on their own to diagnose cancer, tumor markers such as CA-125, PSA, and CEA play an important supporting role in monitoring disease, evaluating treatment response, and, in some cases, flagging the need for further investigation.

What Are Tumor Markers?

Tumor markers are proteins or other substances that can be found in blood, urine, or tissue at higher-than-normal levels when certain cancers are present. Some markers are produced directly by tumor cells, while others are produced by normal cells in response to cancer in the body.

It is important to understand that tumor markers are not exclusive to cancer. Many can also rise due to benign conditions, infections, inflammation, or even normal physiological changes, which is why these tests are used alongside imaging, biopsies, and clinical evaluation rather than as a stand-alone diagnostic tool.

CA-125: Ovarian Cancer Marker

CA-125 is a protein most associated with ovarian cancer. It is often used to monitor women who have already been diagnosed with ovarian cancer, helping doctors track how well treatment is working and watch for signs of recurrence after therapy.

CA-125 is generally not recommended as a screening test for ovarian cancer in women at average risk, because it can be elevated by numerous benign conditions, including endometriosis, uterine fibroids, pelvic inflammatory disease, and even menstruation. Its value lies primarily in monitoring known disease rather than detecting cancer in someone without symptoms.

PSA: Prostate-Specific Antigen

PSA is a protein produced by the prostate gland, and elevated levels are most commonly associated with prostate cancer, though benign prostatic hyperplasia, prostatitis, and even recent ejaculation or a digital rectal exam can also raise PSA temporarily.

PSA testing is used both as a potential early screening tool for prostate cancer in men, particularly those with risk factors such as family history or African ancestry, and as a way to monitor men who have already been treated for prostate cancer to check for signs of recurrence.

CEA: Carcinoembryonic Antigen

CEA is a protein most often associated with colorectal cancer, though it can also be elevated in other cancers, including those of the lung, breast, and pancreas. Like the other markers discussed here, CEA is not considered reliable enough for general population screening.

Its most common clinical use is monitoring patients who have already been diagnosed with colorectal cancer, tracking levels before and after surgery or chemotherapy to assess treatment response, and watching for early signs that the cancer may be returning.

Why These Tests Are Not Used for General Screening

A central theme across CA-125, PSA, and CEA is that none of them are specific enough to confirm cancer on their own. Elevated levels can result from benign, non-cancerous conditions, and some people with cancer may have normal marker levels, particularly in early-stage disease.

Because of this, medical guidelines generally reserve widespread use of these markers for monitoring known cancer patients rather than screening healthy individuals without symptoms, with PSA testing being a notable exception that involves a nuanced, shared decision-making conversation between patient and doctor.

How the Tests Are Performed

All three tests require a simple blood draw and no special preparation in most cases. Results are typically available within a few days. Doctors often track these markers over time rather than relying on a single reading, since a trend of rising or falling values often carries more clinical meaning than one isolated number.

Interpreting Results With Context

An elevated tumor marker should always be interpreted within the context of a person's symptoms, medical history, imaging findings, and, when relevant, biopsy results. A single high reading is rarely a cause for panic on its own, and your doctor will typically recommend additional evaluation before drawing conclusions.

For patients already undergoing cancer treatment, a falling marker level over successive tests is generally a reassuring sign, while a rising trend may prompt further imaging or evaluation to check for recurrence.

Conclusion

Tumor marker tests like CA-125, PSA, and CEA serve as valuable tools for monitoring known cancers and guiding treatment decisions, even though they are not definitive diagnostic tests on their own. Understanding their strengths and limitations helps patients approach these results with appropriate context rather than unnecessary alarm or false reassurance. If you have questions about whether tumor marker testing applies to your situation, a conversation with your doctor can clarify what role, if any, these tests should play in your care.